Investigators conducted a phase 1 trial of intradermal NP2, a novel gene transfer vector, which was found to be safe and well tolerated for the treatment of intractable pain resulting in pain relief in cancer patients who were unresponsive to morphine or other treatments.
Annals of Neurology online April 2011
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment